CSIMarket
 
Galecto Inc   (GLTO)
Other Ticker:  
 
 
Price: $0.7724 $-0.05 -5.563%
Day's High: $0.82 Week Perf: -4.25 %
Day's Low: $ 0.77 30 Day Perf: 13.54 %
Volume (M): 63 52 Wk High: $ 3.70
Volume (M$): $ 48 52 Wk Avg: $1.31
Open: $0.82 52 Wk Low: $0.50



 Market Capitalization (Millions $) 21
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Galecto Inc
Galecto Inc is a biotechnology company that focuses on developing novel therapies to treat fibrosis, cancer, and other related diseases. The company specializes in regulating galectin proteins, which play important roles in various biological processes, including inflammation, tissue remodeling, and cell proliferation. Galecto's pipeline includes potential treatments for conditions such as idiopathic pulmonary fibrosis, liver fibrosis, and pancreatic cancer. The company is known for its expertise in galectin biology and innovative drug discovery approaches, aiming to provide effective therapies for patients with unmet medical needs.


   Company Address: 75 State Street Boston 2109 MA
   Company Phone Number: 70 70 52 10   Stock Exchange / Ticker: NASDAQ GLTO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

MYLOX-1 Trial: GB2064 Monotherapy Proves Effective in Reducing Bone Marrow Fibrosis in Myelofibrosis Patients, Validating LOXL2 as a Promising Clinical Target

Published Thu, Dec 21 2023 9:05 PM UTC

In a groundbreaking clinical trial known as MYLOX-1, promising results have emerged, demonstrating a significant reduction in fibrosis of the bone marrow in patients with myelofibrosis. The trial evaluated the efficacy of GB2064 monotherapy, which successfully led to a 1-grade reduction in collagen fibrosis in six out of ten evaluable patients. These remarkable findings have...

Galecto Inc

Galecto Inc Unveils Impressive Q3 Earnings; Investors Eager to Uncover the Company's Future Performance

Galecto Inc Shows Promising Improvement in Q3 Earnings; Future Performance Under Spotlight
Investors eagerly await the financial performance of Galecto Inc, a prominent player in the healthcare sector, as the company gears up to release its next financial report on March 8, 2024. While stockholders have not factored in some adjustments in the business during the July to September 30, 2023 earnings season, they have noted GLTO's operating deficit, which stood at -$8.583 million during the same period. However, the emerging growth entity has caught investors' attention by demonstrating improved business efficiency compared to the previous fiscal year.
Galecto Inc's journey from an operating deficit of -$13.622 million in the fiscal period ending September 30, 2022, to a positive surprise of -$8.136 million in the third quarter of 2022 echoes the strides the company has made. This reduction in losses positions the firm as a potential frontrunner in the healthcare sector. Investors remain optimistic about Galecto Inc's path to becoming a successful leader in the industry.

Galecto Inc

Galecto Inc Reveals $11.159 Million Operating Deficit in Q2 2023, Surprising Shareholders



Galecto Inc, a company in the biopharmaceutical industry, recently released its financial results for the fiscal period of April to June 2023. While the revenue remained unchanged, significant attention was devoted to the company's operating deficit, which showcased a considerable improvement compared to the previous year. These financial outcomes raise intriguing questions about the company's future prospects.
1. Stable Revenue, but Operating Deficit Raises Concerns:
Shareholders were not anticipating any changes in revenue during the specified earnings cycle. While this stability may offer some reassurance, it is essential to note the substantial operating deficit of $-11.159 million during the same period. This deficit deserves close attention as it has surpassed the previous year's figures. The company's operational decisions during the expansion cycle appear to be a key factor contributing to this observation.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com